Providence Therapeutics Overview
- Founded
-
2015
- Status
-
Private
- Employees
-
63
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$2.12M
- Investors
-
2
Providence Therapeutics General Information
Description
Operator of a biotechnology company intended to create messenger RNA (mRNA) vaccine therapies. The company focuses on oncology research, personalized cancer therapies, drug product development and vaccine manufacturing, enabling clinicians to have access to safe and effective vaccines.
Contact Information
Website
www.providencetherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 120 - 8832 Blackfoot Trail South East
- Calgary, Alberta T2J 3J1
- Canada
+1 (403) 000-0000
Providence Therapeutics Timeline
Providence Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 07-Dec-2021 | $2.12M | 00.00 | Completed | Clinical Trials - Phase 2 | |
| 3. Later Stage VC | 23-Jul-2020 | 00.00 | 00.00 | Completed | Clinical Trials - Phase 2 | |
| 2. Accelerator/Incubator | 01-Feb-2018 | $1.4M | Completed | Clinical Trials - Phase 2 | ||
| 1. Seed Round | 03-Aug-2016 | $1.4M | $1.4M | Completed | Clinical Trials - Phase 2 |
Providence Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Providence Therapeutics Patents
Providence Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3128660-A1 | Compositions and methods for the prevention and/or treatment of covid-19 | Pending | 09-Oct-2020 | 000000000 | |
| CA-3132188-A1 | Compositions and methods for the prevention and/or treatment of covid-19 | Pending | 09-Oct-2020 | 000000000 | |
| CA-3173429-A1 | Compositions and methods for the prevention and/or treatment of covid-19 | Pending | 09-Oct-2020 | 000000000 | |
| CA-3116284-A1 | Compositions and methods for the prevention and/or treatment of covid-19 | Pending | 09-Oct-2020 | 000000000 | |
| CA-3128078-A1 | Compositions and methods for the prevention and/or treatment of covid-19 | Pending | 09-Oct-2020 | A61P31/14 |
Providence Therapeutics Executive Team (8)
Providence Therapeutics Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bradley Sorenson | Providence Therapeutics | Co-Founder, President, Chief Executive Officer & Board Member | 000 0000 |
| Darlene Haslam | Providence Therapeutics | Board Member | 000 0000 |
| Donna Ward JD | Self | Board Member | 000 0000 |
| Eric Marcusson Ph.D | Providence Therapeutics | Co-Founder, Chair of the Sab & Board Member | 000 0000 |
| Ken Hughes | Self | Chairman | 000 0000 |
Providence Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Providence Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Bill & Melinda Gates Foundation | Not-For-Profit Venture Capital | 000 0000 | 000000 0 | ||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | 000 0000 | 000000 0 |